New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

Nublexa (Regorafenib 40mg Tablets)

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

Important Note:

  • Brand Name- Nublexa
  • Innovator Brand Name- Stivarga
  • API- Regorafenib
  • Packaging- 28 Tablets
  • Strength- 40 mg
  • Manufacturer Name- Bayer

South Delhi Pharma can facilitate the supply of “Nublexa (Regorafenib” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Nublexa (Regorafenib is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Categories ,
Categories ,

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

What Nublexa is?

Regorafenib is a multi-kinase inhibitor, indicated for the treatment of:

  • Metastatic Colorectal Cancer
  • Advanced Hepatocellular Carcinoma
  • Also, Advanced Gastoinstenstial Stromal Tumors

What Regorafenib is?

Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types.

Related Products

Related products